Metabolic and bariatric surgery, also known as weight-loss surgery, dramatically improves outcomes for patients with obesity and chronic kidney disease (CKD), significantly reducing the risk of kidney failure, major cardiovascular events and death, according to […]
People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to new research presented at the […]
Glucagonlike peptide-1 (GLP-1) medications have taken over the national conversation around weight loss. From celebrity headlines to everyday conversations, GLP-1 drugs like Ozempic and Wegovy are often framed as breakthroughs and seen as powerful new […]
Being overweight may lead to accelerated cognitive decline, according to new research from the University of Georgia. The paper is published in the Journal of Neurology.This article was originally published on MedicalXpress.com
Inconsistent use of some GLP-1 weight-loss medications, like Ozempic and Wegovy, may significantly lessen their effectiveness, according to a new preclinical study from researchers at the Perelman School of Medicine at the University of Pennsylvania. […]
A new study from the University of St Andrews suggests weight-loss drugs like Ozempic taken around pregnancy do not raise the risk of major birth defects. Published in the American Journal of Obstetrics and Gynaecology, […]
Consumption of ultra-processed foods—including soft drinks, snacks and ready meals—is growing worldwide, despite evidence they are unhealthy.This article was originally published on MedicalXpress.com
The study, published in Nature Medicine, shows that future risk of 18 obesity-related diseases can be predicted using 20 commonly collected health measures, such as blood test results and demographic information. The tool could complement […]
Keeping tabs on blood sugar throughout the day used to be the exclusive domain of people with diabetes. But in 2026, anyone can buy a user-friendly wearable device that provides minute-by-minute readouts on how their […]
The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare, called the BALANCE model, will not launch as scheduled on Jan. 1, 2027.This […]
© 2025 SimplyWell.ca